Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Phentolamine + lidocaine is a combination pharmacological intervention developed by the 988th Hospital of Joint Logistic Support Force of PLA for use during transradial coronary procedures. The combination is designed to mitigate radial artery spasm (RAS), a common complication of radial artery catheterization that can lead to procedural failure and patient discomfort. Phentolamine acts as a non-selective alpha-adrenergic antagonist, blocking alpha-1 and alpha-2 receptors on vascular smooth muscle to induce vasodilation and counteract catecholamine-induced vasoconstriction. Lidocaine, a local anesthetic, blocks voltage-gated sodium channels to provide regional anesthesia at the puncture site and may further stabilize the arterial wall against mechanical stimulation. This spasmolytic cocktail is typically administered via local infiltration or intra-arterial injection to ensure procedural success and improve patient outcomes in interventional cardiology.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on phentolamine + lidocaine.